Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, bevacizumab and irinotecan in recurrent glioblastoma (phase II)
2006-000182-10Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, bevacizumab and irinotecan in glioblastoma (GBM), sponsored by Rigshospitalet. Primary endpoints: Progression-free survival, Response rate and 1 more. Started Apr 2006; status: completed.
02
Drugs
cetuximabbevacizumabirinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2006-000182-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000182-10.